Goldenwell BiotechGWLL 30 Current Ratio is 0.19 as of Mar. 2026, which is 98% below its 10-year median of 8.22. GuruFocus rates GWLL with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,991 Consumer Packaged Goods companies, Goldenwell Biotech ranks worse than 97.89% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Goldenwell Biotech's current ratio for the quarter that ended in Mar. 2026 was 0.19.
Goldenwell Biotech has a current ratio of 0.19. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Goldenwell Biotech has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Goldenwell Biotech's Current Ratio or its related term are showing as below:
GWLL'
s Current Ratio Range Over the Past 10 Years
Min: 0.19 Med: 8.22 Max: 219
Current: 0.19
During the past 6 years, Goldenwell Biotech's highest Current Ratio was 219.00. The lowest was 0.19. And the median was 8.22.
GWLL's Current Ratio is ranked worse than 97.89% of 1991
companies
in the Consumer Packaged Goods industry
Industry Median: 1.73
vs GWLL: 0.19
Goldenwell Biotech (OTCPK:GWLL) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Goldenwell Biotech Current Ratio Related Terms
Goldenwell Biotech Current Ratio Historical Data
* Premium members only.
The historical data trend for Goldenwell Biotech's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Goldenwell Biotech's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Goldenwell Biotech Current Ratio vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Goldenwell Biotech's Current Ratio distribution charts can be found below:
* The bar in red indicates where Goldenwell Biotech's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Goldenwell Biotech (GWLL) has a Current Ratio of 0.19 as of Mar. 2026. This is 98% below median its historical median of 8.22. Over the past decade, Goldenwell Biotech's Current Ratio has ranged from 0.19 to 219.00. According to the industry distribution chart, Goldenwell Biotech ranks #1949 out of 1991 companies in the Consumer Packaged Goods industry, placing it in the top 97.9%.
Is Goldenwell Biotech's Current Ratio too high?
Goldenwell Biotech's current Current Ratio of 0.19 is 98% below median its 10-year median of 8.22. Over the past 10 years, this metric has ranged from a low of 0.19 to a high of 219.00. The Consumer Packaged Goods industry median Current Ratio is 1.73. Goldenwell Biotech's value of 0.19 is 89% below this industry median. Based on the distribution chart, Goldenwell Biotech ranks #1949 out of 1991 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Goldenwell Biotech has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Goldenwell Biotech's Current Ratio compare to HAIN and LSF?
According to the Consumer Packaged Goods industry distribution chart, Goldenwell Biotech ranks #1949 out of 1991 companies for Current Ratio. This places Goldenwell Biotech in the lower half of its industry. The industry median Current Ratio is 1.73. Goldenwell Biotech's value of 0.19 is 89% below this benchmark. Historically, Goldenwell Biotech's own Current Ratio has ranged from 0.19 to 219.00 over the past decade. While the company's 10-year median is 8.22 vs. the industry median of 1.73, Goldenwell Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Consumer Packaged Goods company?
The median Current Ratio among Consumer Packaged Goods companies is 1.73, based on 1,991 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Goldenwell Biotech's current Current Ratio of 0.19 is 89% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Consumer Packaged Goods industry, the median Current Ratio is 1.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Goldenwell Biotech's current Current Ratio is 0.19, which is 98% below median its own 10-year median of 8.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Goldenwell Biotech stock overvalued right now?
Goldenwell Biotech (GWLL) has a current Current Ratio of 0.19. The current Current Ratio is 0.19, which is 98% below median its 10-year median of 8.22 and 89% below the Consumer Packaged Goods industry median of 1.73. Goldenwell Biotech's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Goldenwell Biotech (GWLL), the current Current Ratio is 0.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Goldenwell Biotech Inc is engaged in the research and development, production, and sales of healthcare and supplement products. Its products comprise JI MAI - Bovine Cardiac Vascular Active Peptide, Double Proline AG - 3D Active Collagen Peptide, Cartilage Peptide - Type II collagen peptide, and Sugar Master.
30GF Score
Get the complete analysis for GWLL
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GWLL has been successfully added to your 
